FV-162
FV-162 is a potent, orally active and irreversible proteasome inhibitor. FV-162 exhibits cytotoxic to human myeloma cell lines and primary myeloma cells. FV-162 inhibits tumor growth in a myeloma xenograft mouse model. FV-162 can be used for myeloma research[1].
Product Specifications
CAS Number
[1565822-28-7]
UNSPSC
12352005
Target
Proteasome
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Cancer
Smiles
O=C(C1=CN=C(C)S1)N[C@@H](COC(F)F)C(N[C@@H](COC(F)F)C(N[C@@H](CC2=CC=CC=C2)C([C@]3(CO3)C)=O)=O)=O
Molecular Formula
C25H28F4N4O7S
Molecular Weight
604.57
References & Citations
[1]Wang Z, et al. FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing. Cell Death Dis. 2015 Jul 9;6 (7) :e1815.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
